These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20953791)

  • 1. Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study.
    Anderson G; Meyer D; Herrman CE; Sheppard C; Murray R; Fox EJ; Mathena J; Conner J; Buck PO
    J Neurol; 2010 Nov; 257(11):1917-23. PubMed ID: 20953791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate.
    Pardo G; Boutwell C; Conner J; Denney D; Oleen-Burkey M
    J Neurosci Nurs; 2010 Feb; 42(1):40-6. PubMed ID: 20187348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate.
    Jolly H; Simpson K; Bishop B; Hunter H; Newell C; Denney D; Oleen-Burkey M
    J Neurosci Nurs; 2008 Aug; 40(4):232-9. PubMed ID: 18727339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.
    Wolinsky JS; Borresen TE; Dietrich DW; Wynn D; Sidi Y; Steinerman JR; Knappertz V; Kolodny S;
    Mult Scler Relat Disord; 2015 Jul; 4(4):370-6. PubMed ID: 26195058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.
    Soós N; Shakery K; Mrowietz U
    Am J Clin Dermatol; 2004; 5(5):357-9. PubMed ID: 15554737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.
    Johnson KP; Brooks BR; Ford CC; Goodman AD; Lisak RP; Myers LW; Pruitt AA; Rizzo MA; Rose JW; Weiner LP; Wolinsky JS
    Mult Scler; 2003 Dec; 9(6):585-91. PubMed ID: 14664471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].
    Boyko AN; Alifirova VM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):135-139. PubMed ID: 29265099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endermology: a treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate.
    Lebrun C; Mondot L; Bertagna M; Calleja A; Cohen M
    Clin Neurol Neurosurg; 2011 Nov; 113(9):721-4. PubMed ID: 21839580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
    Ball NJ; Cowan BJ; Moore GR; Hashimoto SA
    J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications.
    Rovaris M; Comi G; Rocca MA; Wolinsky JS; Filippi M;
    Brain; 2001 Sep; 124(Pt 9):1803-12. PubMed ID: 11522582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA; Rovaris M; Goodman AD; Ladkani D; Wynn D; Filippi M;
    Neurology; 2007 Mar; 68(12):939-44. PubMed ID: 17372130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
    Khan O; Rieckmann P; Boyko A; Selmaj K; Zivadinov R;
    Ann Neurol; 2013 Jun; 73(6):705-13. PubMed ID: 23686821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection--a case report.
    Zecca C; Mainetti C; Blum R; Gobbi C
    BMC Neurol; 2015 Dec; 15():249. PubMed ID: 26630967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A patient care program for adjusting the autoinjector needle depth according to subcutaneous tissue thickness in patients with multiple sclerosis receiving subcutaneous injections of glatiramer acetate.
    Masid ML; Ocaña RH; Gil MJ; Ramos MC; Roig ME; Carreño MR; Morales JC; Carrasco ML; Hidalgo LM; Felices AM; Castaño AH; Romero PC; Martinez PF; Sánchez-De la Rosa R
    J Neurosci Nurs; 2015 Feb; 47(1):E22-30. PubMed ID: 25225835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glatiramer acetate-induced lobular panniculitis and skin necrosis.
    Watkins CE; Litchfield J; Youngberg G; Leicht SS; Krishnaswamy G
    Cutis; 2015 Mar; 95(3):E26-30. PubMed ID: 25844792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.
    Johnson KP; Ford CC; Lisak RP; Wolinsky JS
    Acta Neurol Scand; 2005 Jan; 111(1):42-7. PubMed ID: 15595937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of multiple sclerosis with glatiramer acetate. Current aspects of mechanisms of action, pharmacokinetics, adverse effect profile and clinical studies].
    Ziemssen T; Neuhaus O; Farina C; Hartung HP; Hohlfeld R
    Nervenarzt; 2002 Apr; 73(4):321-31. PubMed ID: 12040979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis.
    Ziemssen T; Ashtamker N; Rubinchick S; Knappertz V; Comi G
    Expert Opin Drug Saf; 2017 Feb; 16(2):247-255. PubMed ID: 27989217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.